,18 Whether VEGF-neutralizing therapies are driving the core elements of non-exudative AMD or it is simply a natural underlying progression, there is a clear need to simultaneously treat both the exudative and non-exudative elements of AMD to optimize clinical outcomes. The gene discussed is VEGFA; the disease is age-related macular degeneration.